MedicaidPrior AuthLow impact
Alpha-1 Proteinase Inhibitors (Aralast NP®, Glassia®, Prolastin-C®, Zemaira®) (Revised)
Humana·LA · Pulmonology, Internal Medicine·Medicaid
Effective date
Jan 1, 2026
We identified it
Jun 24, 2026
Summary
Humana has updated prior authorization requirements for Alpha-1 Proteinase Inhibitors (Aralast NP, Glassia, Prolastin-C, Zemaira) for Louisiana Medicaid members. The policy specifies strict criteria including specific phenotypes, serum concentration levels, and excludes IgA deficient patients.
Action Required
By January 1, 2026: Billing team must ensure prior authorization is obtained for Alpha-1 Proteinase Inhibitors (Aralast NP, Glassia, Prolastin-C, Zemaira) for Louisiana Medicaid patients. Verify patients meet all three criteria: congenital alpha1-antitrypsin deficiency with emphysema, specific phenotypes (PiZZ, PiZ(null), or Pi(null,null)), and serum concentrations <57mg/dL (nephelometry) or <80mg/dL (radial immunodiffusion). Exclude IgA deficient patients. Claims will be denied without proper prior authorization.